Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos

19. august 2026 opdateret af: Pfizer
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework

Studieoversigt

Status

Aktiv, ikke rekrutterende

Undersøgelsestype

Observationel

Tilmelding (Anslået)

293334

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10001
        • Pfizer

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

The study population will include non-pregnant adults aged ≥18 years and ≥ 60 years in the United States with care observed in Epic Cosmos, contributing healthcare systems on or after August 2023. Individuals will be required to have sufficient healthcare engagement to ensure adequate data capture and observability within the database. Within this population, vaccinated individuals will be identified by documented administration of an RSV vaccine in structured EHR data.

Beskrivelse

Inclusion: Vaccinated Cohort

Patients must meet all the following inclusion criteria to be eligible for inclusion in the vaccinated cohort:

Adults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.

Have a documented administration of ABRYSVO® (or AREXVY®,mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.

The index date for vaccinated individuals will be defined as the date of RSV vaccination.

Unvaccinated Cohort

Patients must meet all the following inclusion criteria to be eligible for inclusion in the unvaccinated cohort:

Adults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.

Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.

The index date for unvaccinated individuals will be defined as the start date of each sequential trial (e.g., 1st date of each month) in which they met eligibility criteria.

Exclusion:

Vaccinated Cohort

Patients meeting any of the following criteria will not be included in the vaccinated cohort:

Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).

Non-US residents. Unvaccinated Cohort

Patients meeting any of the following criteria will not be included in the unvaccinated cohort:

Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.

Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Vaccinated group
Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna)
Unvaccinated comparator group:
Individuals not yet vaccinated at cohort entry, but otherwise eligible

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
Tidsramme: up to 3 years
up to 3 years
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
Tidsramme: up to 3 years
up to 3 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of RSV-related outcomes
Tidsramme: up to 3 years
ARI/LRTD non-inpatient encounter, ARI/LRTD severe outcome, ARI/LRTD critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, and pneumonia with different care settings.
up to 3 years
Incidence of All-cause outcomes
Tidsramme: up to 3 years
all-cause ARI/LRTD encounter with different care settings, severe outcome, critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, pneumonia with different care settings, and dementia (new onset).
up to 3 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. juni 2026

Primær færdiggørelse (Anslået)

30. september 2026

Studieafslutning (Anslået)

30. september 2026

Datoer for studieregistrering

Først indsendt

22. juni 2026

Først indsendt, der opfyldte QC-kriterier

22. juni 2026

Først opslået (Faktiske)

29. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • C3671094

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner